Connect with us
Prague Gaming & TECH Summit 2024

Fintech PR

Partnership to focus on Alzheimer’s disease, breast cancer, diabetes, obesity

Published

5 years ago

on

Reading Time: 8 minutes

 

Centene Corporation (NYSE: CNC) and Washington University School of Medicine in St. Louis announced today a partnership to transform and accelerate research into treatments for Alzheimer’s disease, breast cancer, diabetes and obesity. All are common, debilitating and often deadly diseases that affect millions of people worldwide, at all levels of income.

As part of the partnership, Centene will fund up to $100 million over 10 years in research at Washington University. The funding will galvanize the School of Medicine’s Personalized Medicine Initiative, which aims to develop customized disease treatment and prevention for patients. Innovations that arise from the initiative will be commercialized through the ARCH Personalized Medicine Initiative, a joint venture between the School of Medicine and Centene. Reflecting the philosophy of both institutions, ARCH is designed to accelerate the development and implementation of affordable and accessible health solutions to the public using the intellectual property developed from this research.

“We share the goal of helping to improve the health of our communities through research, education and customized treatment for people suffering from chronic illnesses,” said Michael F. Neidorff, chairman and CEO for Centene. “We believe personalized medicine is the path to ensure patients get the targeted health care they need to fight disease, and we look forward to partnering with such a renowned medical school to initially focus on four diseases that impact millions of Americans, including many of our health plan members.”

The investment will leverage the university’s cutting-edge research and biomedical capabilities, including state-of-the-art technologies such as CRISPR, and internationally known scientists in the areas of the microbiome, immunomodulatory therapies, cancer genomics, neurodegeneration, cellular reprogramming, chemical biology, informatics and others. In addition, the funds will strengthen resources at more than a dozen centers and institutes at the School of Medicine, including the Edison Family Center for Genome Sciences & Systems Biology; the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; the Elizabeth H. and James S. McDonnell III Genome Institute; the Institute for Informatics; and the Center of Regenerative Medicine.

“We will be bringing together world-class resources and intellectual horsepower from every basic and clinical scientific discipline to urgently accelerate the timeline for developing therapies that are more precisely targeted, with aspirations to do so in the next five to seven years,” said David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean, and the Spencer T. and Ann. W. Olin Distinguished Professor at the School of Medicine. “I believe the most important advances that will evolve from the personalized medicine paradigm will come from harnessing genome engineering technologies to build better model systems of each human disease, and utilizing deep genomic and clinical characterization to enable more effective and less expensive clinical trials.”

Perlmutter continued, “The partnership supports our global leadership in understanding sequence variants in biological systems that will pave the way for new therapeutic targets, as well as learning more about our own innate biology. Once personalized medicine becomes common practice, health-care workers may examine each patient’s genome — as well as information regarding his or her environment, lifestyle and social network — to identify a customized, affordable approach to optimizing health and medical care.”

Centene and Washington University will host a press briefing at a later date to be determined.

About Centene Corporation
Centene Corporation, a Fortune 100 company, is a diversified, multi-national healthcare enterprise that provides a portfolio of services to government sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children’s Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long-Term Services and Supports (LTSS), in addition to other state-sponsored programs, Medicare (including the Medicare prescription drug benefit commonly known as “Part D”), dual eligible programs and programs with the U.S. Department of Defense. Centene also provides healthcare services to groups and individuals delivered through commercial health plans. Centene operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health management, care management software, correctional healthcare services, dental benefits management, commercial programs, home-based primary care services, life and health management, vision benefits management, pharmacy benefits management, specialty pharmacy and telehealth services.

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene’s investor relations website, http://www.centene.com/investors.

About Washington University School of Medicine in St. Louis
Washington University School of Medicine’s 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.

Cautionary Statement on Forward-Looking Statements

All statements, other than statements of current or historical fact, contained in this communication are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “seek,” “target,” “goal,” “may,” “will,” “would,” “could,” “should,” “can,” “continue” and other similar words or expressions (and the negative thereof). We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and Centene Corporation is including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about Centene’s future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of Centene’s proposed acquisition of WellCare Health Plans, Inc. (the “WellCare Transaction”), Centene’s recent acquisition (the “Fidelis Care Transaction”) of substantially all the assets of New York State Catholic Health Plan, Inc., d/b/a Fidelis Care New York (“Fidelis Care“), investments and the adequacy of Centene’s available cash resources.

These forward-looking statements reflect Centene’s current views with respect to future events and are based on numerous assumptions and assessments made by us in light of Centene’s experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors Centene believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause Centene’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions.

All forward-looking statements included in this filing are based on information available to us on the date of this communication. Except as may be otherwise required by law, Centene undertakes no obligation to update or revise the forward-looking statements included in this communication, whether as a result of new information, future events or otherwise, after the date of this filing. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to, the following: (i) the risk that regulatory or other approvals required for the WellCare Transaction may be delayed or not obtained or are obtained subject to conditions that are not anticipated that could require the exertion of management’s time and Centene’s resources or otherwise have an adverse effect on Centene; (ii) the risk that Centene’s stockholders do not approve the issuance of shares of Centene common stock in the WellCare Transaction; (iii) the risk that WellCare’s stockholders do not adopt the merger agreement; (iv) the possibility that certain conditions to the consummation of the WellCare Transaction will not be satisfied or completed on a timely basis and accordingly the WellCare Transaction may not be consummated on a timely basis or at all; (v) uncertainty as to the expected financial performance of the combined company following completion of the WellCare Transaction; (vi) the possibility that the expected synergies and value creation from the WellCare Transaction will not be realized, or will not be realized within the expected time period; (vii) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required, in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for the WellCare Transaction; (viii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of the WellCare Transaction or that the integration of WellCare will be more difficult or time consuming than expected; (ix) the risk that potential litigation in connection with the WellCare Transaction may affect the timing or occurrence of the WellCare Transaction or result in significant costs of defense, indemnification and liability; (x) a downgrade of the credit rating of Centene’s indebtedness, which could give rise to an obligation to redeem existing indebtedness; (xi) unexpected costs, charges or expenses resulting from the WellCare Transaction; (xii) the possibility that competing offers will be made to acquire WellCare; (xiii) the inability to retain key personnel; (xiv) disruption from the announcement, pendency and/or completion of the WellCare Transaction, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; and (xv) the risk that, following the WellCare Transaction, the combined company may not be able to effectively manage its expanded operations.

Additional factors that may cause actual results to differ materially from projections, estimates, or other forward-looking statements include, but are not limited to, the following: (i) Centene’s ability to accurately predict and effectively manage health benefits and other operating expenses and reserves; (ii) competition; (iii) membership and revenue declines or unexpected trends; (iv) changes in healthcare practices, new technologies, and advances in medicine; (v) increased healthcare costs, (vi) changes in economic, political or market conditions; (vii) changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act, collectively referred to as the Affordable Care Act (“ACA”), and any regulations enacted thereunder that may result from changing political conditions or judicial actions, including the ultimate outcome of the District Court decision in “Texas v. United States of America” regarding the constitutionality of the ACA; (viii) rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting Centene’s government businesses; (ix) Centene’s ability to adequately price products on federally facilitated and state-based Health Insurance Marketplaces; (x) tax matters; (xi) disasters or major epidemics; (xii) the outcome of legal and regulatory proceedings; (xiii) changes in expected contract start dates; (xiv) provider, state, federal and other contract changes and timing of regulatory approval of contracts; (xv) the expiration, suspension, or termination of Centene’s contracts with federal or state governments (including but not limited to Medicaid, Medicare, TRICARE or other customers); (xvi) the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; (xvii) challenges to Centene’s contract awards; (xviii) cyber-attacks or other privacy or data security incidents; (xix) the possibility that the expected synergies and value creation from acquired businesses, including, without limitation, the Fidelis Care Transaction, will not be realized, or will not be realized within the expected time period; (xx) the exertion of management’s time and Centene’s resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions, including the Fidelis Care Transaction; (xxi) disruption caused by significant completed and pending acquisitions, including, among others, the Fidelis Care Transaction, making it more difficult to maintain business and operational relationships; (xxii) the risk that unexpected costs will be incurred in connection with the completion and/or integration of acquisition transactions, including, among others, the Fidelis Care Transaction; (xxiii) changes in expected closing dates, estimated purchase price and accretion for acquisitions; (xxiv) the risk that acquired businesses, including Fidelis Care, will not be integrated successfully; (xxv) the risk that, following the Fidelis Care Transaction, Centene may not be able to effectively manage its expanded operations; (xxvi) restrictions and limitations in connection with Centene’s indebtedness; (xxvii) Centene’s ability to maintain the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; (xxviii) availability of debt and equity financing, on terms that are favorable to us; (xxxix) inflation; and (xxx) foreign currency fluctuations.

This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect Centene’s business operations, financial condition and results of operations, in Centene’s filings with the Securities and Exchange Commission (the “SEC”), including Centene’s Annual Report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.  Due to these important factors and risks, Centene cannot give assurances with respect to Centene’s future performance, including without limitation Centene’s ability to maintain adequate premium levels or Centene’s ability to control its future medical and selling, general and administrative costs.

 

SOURCE: Centene Corporation

Related Topics:
Continue Reading

Fintech PR

Aragon OSx and App Launch on Arbitrum: lowering the cost and time of launching a DAO

Published

1 hour ago

on

November 30, 2023

By

aragon-osx-and-app-launch-on-arbitrum:-lowering-the-cost-and-time-of-launching-a-dao

Both Arbitrum and Aragon are building gateways to the largest layer 1 ecosystem, Ethereum

ZUG, Switzerland, Nov. 30, 2023 /PRNewswire/ — Aragon has deployed its modular Aragon OSx DAO framework and no-code Aragon App on Arbitrum, opening the door for DAOs to interact with a thriving ecosystem of protocols, applications, and assets. Arbitrum’s rollup technology serves as a gateway to the largest Layer 1 ecosystem—Ethereum—and Aragon’s user-friendly tech stack unlocks the mass adoption of DAO technology.

With over $7 billion total value locked and 55% of the L2 market share, Arbitrum is the industry’s most popular L2 solution. By launching on Arbitrum, DAOs can benefit from lower gas costs, allowing them to conserve DAO resources and drive increased voter turnout. Building custom DAOs on Arbitrum is also easy, because developers can take advantage of full EVM equivalence that streamlines the deployment of custom integrations. Additionally, builders who deploy on Arbitrum inherit the time-proven security of Ethereum, providing a safer and better experience for users, and can enjoy faster transaction speeds that reduce the time needed for DAO administration and governance.

“Arbitrum is by far the most adopted rollup in the EVM ecosystem, both in terms of TVL and protocols launched on the network,” said Ivan Fartunov, Head of Ecosystem at Aragon. “In addition to being home to impactful multichain projects like Stargate, Arbitrum has spurred many exciting native projects like GMX, Tenderize, and Plutus. We are excited to join such a vibrant ecosystem.”

With the accessibility of its no-code solutions, over 7000 DAOs have been launched with Aragon across Ethereum L1 and L2s. Arbitrum communities can now launch a DAO in under 10 minutes and manage their assets in a transparent and user-friendly app.

In addition, the secure and modular design of Aragon OSx enables protocols deployed on Arbitrum to customize their governance with plugins, including multichain governance and optimistic dual governance.

Arbitrum and Aragon are both building technology that opens doors to Ethereum. Both projects have a shared vision to bring the world onto Ethereum through more accessible gateways. More information about Aragon OSx and the Aragon App can be found at https://aragon.org/

About Aragon:

Aragon builds the secure and modular Aragon OSx DAO framework and no-code Aragon App. Aragon deployed the first DAO framework in 2017, which has powered the creation of over 7500 DAOs and secured over $16b in value for leading projects like Lido, Decentraland, API3, Aavegotchi, and NFTX.

 

View original content:https://www.prnewswire.co.uk/news-releases/aragon-osx-and-app-launch-on-arbitrum-lowering-the-cost-and-time-of-launching-a-dao-302002016.html

Continue Reading

Fintech PR

Global Securities Brokerage & Stock Exchange Services Market Size Expected to Reach $1.84 Trillion In 2023

Published

1 hour ago

on

November 30, 2023

By

global-securities-brokerage-&-stock-exchange-services-market-size-expected-to-reach-$1.84-trillion-in-2023

*No Investment Advice Provided*

PALM BEACH, Fla., Nov. 30, 2023 /PRNewswire/ — Stock brokerage is a financial organization on the stock or commodity markets who buys and sells assets in the client’s best interest for which brokerage fee is charged. A stock exchange is a standardized and authorized marketplace where stockbrokers and traders can buy and sell stocks, bonds, and other securities. The services are offered through various modes, such as online and online modes. The various establishments involved are exclusive brokers, banks, investment firms, and other establishments.  The securities brokerage and stock exchange services market consist of revenues earned by entities by acting as brokers in selling securities such as equities, bonds, commodities and derivatives. Securities brokerages represent customers in dealing with securities transactions on the trading floor/online platform of stock exchanges. The securities brokerages might sometimes act as a representative for both buyer and seller. This market excludes the advisory and investment activities of the brokerage firms. This market includes transaction charges levied by stock exchanges for trading on its trading floor/online platform to securities brokerages and other fees. It does not include the value of the funds invested in securities. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The rise in the use of AI for faster trade executions is the main driver of the market.  A report from The Business Research Company projected that the global securities brokerage and stock exchange services market size grew from $1696.91 Billion in 2022 to $1844.31 Billion in 2023 at a compound annual growth rate (CAGR) of 8.7%.  The market size of global securities brokerage and stock exchange services market is expected to grow to $2506.41 billion in 2027 at a CAGR of 8.0%.  Mentioned in today’s coverage includes: EF Hutton, JPMorgan Chase & Co. (NYSE: JPM), Jefferies Financial Group Inc. (NYSE: JEF), Goldman Sachs (NYSE: GS), Bank of America Corporation (NYSE: BAC), Citigroup Inc. (NYSE: C).

The report added: “Securities brokerage companies are extensively using artificial intelligence for faster trade executions. Artificial intelligence refers to programming machines to enable them to work and react like humans. Most companies are using AI for algorithmic trading in stock brokerage. Algorithmic trading refers to turning a trading idea into an algorithmic trading strategy using an algorithm. The AI-enabled alternative trading system (ATS) helps in improving the speed of trade execution.  North America was the largest region in the securities brokerage and stock exchange services market size in 2022. South America was the second largest region in the securities brokerage and stock exchange services.”

EF Hutton Completes Acquisition of Broker-Dealer Benchmark Investments, LLC – EF Hutton, an investment bank headquartered in New York, today announced the closing of the acquisition of its broker-dealer, Benchmark Investments, LLC, a provider of a range of financial services to institutional and retail clients.

The transaction closed on November 9, 2023, significantly expanding EF Hutton’s capabilities and leadership across public and private markets for its growing roster of clients, with all broker-dealer resources and operations to be held under the EF Hutton brand. Benchmark Investments, LLC name has been changed to “EF Hutton LLC.”  Additional details of the transaction were not disclosed.

“This transformative acquisition is the next step in our evolution to help our clients’ ambitions prosper through a full spectrum of services,” said Joseph T. Rallo, Chief Executive Officer of EF Hutton. “Looking ahead, we are integrating broker-dealer operations and believe this transaction will enhance our current business lines with the capacity for larger deals and a broader client base, while also providing a platform to expand our business lines in the future. We continue to look for additional opportunities to bolster our services and strengthen our footprint, including the expansion of our retail business through our wealth management division,” concluded Rallo.

David W. Boral, President of EF Hutton, added, “Incorporating broker-dealer functions and services into the firm will bring a higher degree of streamlined operations and efficiency for our clients. This acquisition also provides us with additional independence that gives more control and transparency to the deal process from start to finish. Our improved end-to-end solutions will position clients for long-term success across IPOs, SPAC IPOs, follow-on offerings, secondary offerings, shelf takedowns, M&A, advisory, acquisition financings, pre-IPO financings, and more. We look forward to introducing middle market and emerging growth companies around the world to an expanded EF Hutton.” For more information on EF Hutton, please visit:  https://efhutton.com/ef-hutton-news/

Other recent developments in the financial markets of note include:

JPMorgan Chase & Co. (NYSE: JPM) recently kicked off its second annual DEVUP, a firmwide software engineering conference designed for engineers by engineers. Launched in 2022, DEVUP is a one-of-a-kind technology innovation forum convening more than 500 software engineers, data scientists and other technologists from all 23 of the financial services firm’s Global Technology Centers for three days of programming that celebrate engineering excellence.

The agenda features wide-ranging discussions on cutting-edge research, interactive workshops, and hands-on experiences led by more than 150 speakers. Participants have the unique opportunity to showcase and learn skills, build connections with peers, and discuss new ways to implement emerging technologies at massive scale and speed at one of the world’s large financial institutions.

“In today’s dynamic technology landscape, the role of the software engineer – and the technologist more broadly – is undergoing a transformative shift. DEVUP is an opportunity to recognize JPMorgan Chase’s top software engineers, provide experiences for them to build their skills, and foster a sense of community – all with the aim of empowering them to continue driving innovation across our firm,” said Lori Beer, Global Chief Information Officer, JPMorgan Chase. “Already a beloved tradition among JPMorgan Chase’s technologists in its second year, DEVUP brings together our software engineers from across the world to explore opportunities for innovation and impact, and champion the broader firm’s technology-forward mindset.”

Bank of America Corporation (NYSE: BAC) Chair and Chief Executive Officer Brian Moynihan will participate in the Goldman Sachs 2023 US Financial Services Conference on Tuesday, December 5, at 9:20 a.m. ET.  A live webcast of this event will be accessible through the Bank of America Investor Relations website at https://investor.bankofamerica.com.

Citigroup Inc. (NYSE: C) – Citibank is launching its first football promotional campaign in Singapore, giving its customers a once-in-a-lifetime opportunity to attend the prestigious UEFA Champions League Final live in London.

The global bank is the first in Singapore to partner Mastercard for the 2023/24 UEFA Champions League, responding to the passion points of its clients and the intense popularity of football in the region.

Regina Lim, Citibank Singapore Head of Credit Cards and Personal Loans, said: “Customers want a win-win relationship with a bank that understands and empowers them to pursue their passion. Given the immense following football has in Singapore, this campaign exemplifies our commitment to be the bank that gets our customers ahead and delivers exceptional value for them.

Jefferies Financial Group Inc. (NYSE: JEF) Richard Handler, CEO, and Brian Friedman, President recently released a statement regarding the firm’s Q3 Financial highlights.

“Our third quarter net revenues of $1.18 billion reflect an improving market environment. We are increasingly optimistic that we have come off the bottom of the cycle and that momentum in investment banking will continue.

“Investment Banking generated $645 million of net revenues, an increase of 28% from last quarter due to modestly improved mergers and acquisitions activity and a more receptive leveraged finance and new issue market, as the green shoots we mentioned last quarter have multiplied.”

“Our strategy during down cycles has always been to play offense by investing in our future. This is the main theme for us in 2023, made possible by our strong capital base and solid global brand and platform. The dislocation and changes in strategy among some of our competitors created distinct opportunity this year. As we will discuss during our upcoming Investor Day on October 16, 2023, we are adding outstanding new Managing Directors to our Investment Banking effort across the globe. We started 2023 with 299 Managing Directors in Investment Banking and expect to begin 2024 with over 360 total Managing Directors, an increase of 20%. The 360 Managing Directors would be up 70% from the 212 Investment Banking Managing Directors that wore the Jefferies’ jersey at the beginning of 2020.”

Goldman Sachs (NYSE: GS) recently recognized CEO of 6sense, Jason Zintak, as one of the Most Exceptional Entrepreneurs of 2023 at its Builders and Innovators Summit in Healdsburg, California.  Goldman Sachs selected Zintak from multiple industries honored at the two-day event. Since Zintak joined 6sense in 2017, the company has grown astronomically by every measure: employee, customer, net revenue retention, and revenue growth. With a reputation for making smart moves, prioritizing people, and creating a culture of innovation, Zintak leads the company towards its mission to revolutionize the way B2B organizations create, manage and convert pipeline to revenue.

“To be recognized for entrepreneurship by Goldman Sachs is an incredible honor,” said Jason Zintak, 6sense CEO. “This recognition reflects the strength and passion of our team and our commitment to a growth mindset which fosters ongoing learning, curiosity and innovation. Our collective entrepreneurial spirit at 6sense started with our founders and leaders and continues today across the organization as a defining element of our success in delivering real value to our customers.”

About FN Media Group:

At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies.

Follow us on Facebook to receive emerging news updates: https://www.facebook.com/financialnewsmedia.
Follow us on Twitter for real time Breaking News: https://twitter.com/FNMgroup.
Follow and us on LinkedIn: https://www.linkedin.com/in/financialnewsmedia/.

DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNM is NOT affiliated in any manner with any company mentioned herein.  FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNM expects to be compensated twenty six hundred dollars for news coverage of the current press releases issued by Homerun Resources Inc.  by a non-affiliated third party.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:
Media Contact email: [email protected]; +1(561)325-8757

View original content:https://www.prnewswire.co.uk/news-releases/global-securities-brokerage–stock-exchange-services-market-size-expected-to-reach-1-84-trillion-in-2023–302001960.html

Continue Reading

Fintech PR

CHARAC SECURES £1M INVESTMENT FROM WORLD-CLASS MEDICATION PLATFORM MEDADVISOR TO DRIVE ITS INTERNATIONAL GROWTH

Published

1 hour ago

on

November 30, 2023

By

charac-secures-1m-investment-from-world-class-medication-platform-medadvisor-to-drive-its-international-growth

Total capital raised by Charac now sits at £3.5 million following previous investment from the National Pharmacy Association

Deal allows Charac to expand its capabilities across Australia, New Zealand and the USA to help pharmacists capitalise on significant market opportunities

LONDON, Nov. 28, 2023 /PRNewswire/ — Leading healthcare SaaS provider Charac today announces a ground-breaking partnership with world-class medication management platform MedAdvisor Solutions (ASX:MDR). The deal with Australia-based MedAdvisor allows Charac to expand it capabilities across Australia, New Zealand and the USA, making components of its app available to a far broader group of pharmacies internationally.

MedAdvisor, through a strategic investment and licencing agreement, will invest up to £1 million over 9-months in Charac for up to a 7.4% shareholding, and the company’s CEO Rick Ratliff will join Charac’s board as a Non-Executive Director.  MedAdvisor will end operations in the UK, transferring its relationships to Charac.

Through licensing specific components of Charac’s platform and integrating them into MedAdvisor’s Plus One platform, the partnership will provide tremendous improvements in the delivery of digital pharmacy support, advanced home delivery solutions and eCommerce capabilities.

MedAdvisor has connected with over 3.5 million patients through more than 95% of Australian community pharmacies. It also serves 25% of New Zealand’s community pharmacies and works with 33,500 pharmacies in the USA. Globally, MedAdvisor has achieved a milestone of 235 million patients.

Charac’s app streamlines pharmacy operations onto a cloud-native platform to relieve time pressure, increase efficiency and drive the growth of independent pharmacies.

The UK’s retail pharmacy market is projected to grow from USD$27b in 2022 to $39.59b by 2030. In Australia, revenue in the pharmacies market is close to USD$20b, while in the USA, the market is valued at some USD$527b. All three markets have annual growth projections of between 4%-5%.

Charac is integrated with the NHS, and the company has signed up some 800 pharmacies, with 36,000 patients currently using the app. Charac has previously secured a £1 million investment from the Royal Mail and £1.2 million from the National Pharmacy Association and pharmacy owners.

Santosh Sahu, founder and CEO of Charac, said: “MedAdvisor is an ideal partner for us to help accelerate our international growth plans and pursue our ambitious mission to enable pharmacies to take advantage of the significant opportunities that present themselves.”

View original content:https://www.prnewswire.co.uk/news-releases/charac-secures-1m-investment-from-world-class-medication-platform-medadvisor-to-drive-its-international-growth-302002244.html

Continue Reading

Trending